Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis

Next Previous
Trial Profile

A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Therapeutic Use
  • Sponsors GW Pharmaceuticals; Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 28 Oct 2022 Results of post hoc analysis assessing the long-term dosage of nabiximols, to evaluate real-world dosing and to investigate the association between dosage and premature study discontinuation in MS-related spasticity from GWMS1137 (n=62) and GWSR10128 (N=765) studies, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 22 Apr 2021 Results assessing effect of nabiximols on depression, suicidality, and cognition using data from GWSP0604 (12 weeks; n=241) and GWMS1137 (48 weeks; n=121) trials in persons with multiple sclerosis with inadequately managed spasticity, presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 13 Apr 2021 According to a GW Pharmaceuticals media release, results from two studies GWSP0604 and GWMS1137 (abstract no P15.185) presented at the 2021 American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top